About Immunorock
Immunorock is a company based in Kobe (Japan) founded in 2021.. Immunorock has raised $2.59 million across 4 funding rounds from investors including Future Venture capital, Osaka University Venture Capital and Kobe University Capital. Immunorock operates in a competitive market with competitors including VBI Vaccines, Imvax, Pardes Biosciences, BriaCell Therapeutics and ExeVir Bio, among others.
- Headquarter Kobe, Japan
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$2.59 M (USD)
in 4 rounds
-
Latest Funding Round
$315.39 K (USD), Seed
Dec 01, 2025
-
Investors
Future Venture capital
& 3 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Immunorock
Immunorock has successfully raised a total of $2.59M across 4 strategic funding rounds. The most recent funding activity was a Seed round of $315.39 thousand completed in December 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Seed — $315,395
-
First Round
First Round
(13 Jul 2023)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2025 | Amount | Seed - Immunorock | Valuation |
investors |
|
| Jul, 2025 | Amount | Seed - Immunorock | Valuation |
investors |
|
| Apr, 2024 | Amount | Seed - Immunorock | Valuation | Osaka University Venture Capital |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Immunorock
Immunorock has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Future Venture capital, Osaka University Venture Capital and Kobe University Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Venture capital services are provided by Kobe University Capital.
|
Founded Year | Domain | Location | |
|
Early-stage investments are made by Future Venture Capital in Japan.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Immunorock
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Immunorock
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Immunorock Comparisons
Competitors of Immunorock
Immunorock operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as VBI Vaccines, Imvax, Pardes Biosciences, BriaCell Therapeutics and ExeVir Bio, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
VBI Vaccines is engaged in developing vaccines and immunotherapeutics.
|
|
| domain | founded_year | HQ Location |
Patient-specific cell vaccines for glioma treatment are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for pandemic diseases including SARS-CoV-2 are developed.
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies for the treatment of cancer
|
|
| domain | founded_year | HQ Location |
Provider of antibody-based therapies to monitor viral infections
|
|
| domain | founded_year | HQ Location |
Vaccines for neurological disorders and infectious diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Immunorock
Frequently Asked Questions about Immunorock
When was Immunorock founded?
Immunorock was founded in 2021 and raised its 1st funding round 2 years after it was founded.
Where is Immunorock located?
Immunorock is headquartered in Kobe, Japan. It is registered at Kobe, Hyogo, Japan.
Who is the current CEO of Immunorock?
Toshiro Shirakawa is the current CEO of Immunorock.
Is Immunorock a funded company?
Immunorock is a funded company, having raised a total of $2.59M across 4 funding rounds to date. The company's 1st funding round was a Seed of $292.47K, raised on Jul 13, 2023.
What does Immunorock do?
Immunorock was founded in 2021 in Kobe, Japan, within the biotechnology sector. Focus is placed on immunotherapies for cancer and infectious diseases, utilizing an innovative oral vaccine platform. Key developments include the B440 WT1 oral cancer vaccine and the BCOV332 oral COVID vaccine. Operations center on advancing these treatments through research and clinical pathways.
Who are the top competitors of Immunorock?
Immunorock's top competitors include Imvax, VBI Vaccines and BriaCell Therapeutics.
Who are Immunorock's investors?
Immunorock has 4 investors. Key investors include Future Venture capital, Osaka University Venture Capital, Kobe University Capital, and SBI Daigaku Hatsu Venture Ikusei Shien.